References
- Grootendorst P, Piérard E, Shim M. Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature. Expert Rev. Pharmacoeconomics Outcomes Res.9(4), 353–364 (2009).
- Crémieux PY, Meilleur MC, Ouellette P et al. Public and private pharmaceutical spending as determinants of health outcomes in Canada. Health Econ.14(2), 107–116 (2005).
- Frech HE, Miller RD. The effects of pharmaceutical consumption and obesity on the quality of life in the OECD countries. Pharmacoeconomics22(Suppl.), 25–36 (2004).
- Shaw JW, Horrace WC, Vogel RJ. The determinants of life expectancy: an analysis of the OECD health data. South Econ. J.71(4), 768–783 (2005).
- Lichtenberg FR. Sources of U.S. longevity increase, 1960–2001. Q. Rev. Econ. Finance44, 369–389 (2004).
- Grossman GM, Helpman E. Innovation and Growth in the Global Economy. MIT Press, MA, USA (1993).
- Bresnahan TF, Gordon RJ. The Economics of New Goods. University of Chicago Press, IL, USA (1996).
- Jones C. Introduction to Economic Growth. Norton, NY, USA (1998).
- Lichtenberg FR. Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995–2003. Health Economics18(5), 519–534 (2009).
- Specter M. Denialism: How Irrational Thinking Hinders Scientific Progress, Harms the Planet and Threatens Our Lives. The Penguin Press, London, UK (2009).
- Angell M. The Truth About the Drug Companies: How They Deceive Us and What To Do About It. Random House, NY, USA (2005).
- Light D. What’s so great about newness? Health Affairs26(6), 1793 (2007).
- Jung KT, Kim JY, Lichtenberg FR. The effect of drug vintage on mortality: economic effect of new drugs. Korean J. Health Policy Admin.16(4), 147–168 (2006).
- Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P. The impact of drug vintage on patient survival: a patient-level analysis using Quebec’s provincial health plan data. Value Health12(6), 847–856 (2009).
- Solow R. Investment and Technological Progress, in Mathematical Methods in Social Sciences 1959. Arrow K, Karlin S, Suppes P (Eds). Stanford University Press, CA, USA, 89–104 (1960).
- Bahk B, Gort M. Decomposing learning by doing in new plants. J. Political Economy101, 561–583 (1993).
- Hulten CR. Growth accounting when technical change is embodied in capital. Am. Economic Rev.82(4), 964–980 (1992).
- Sakellaris P, Wilson D. The production-side approach to estimating embodied technological change. In: Finance and Economics Discussion Series 2001-20. Board of Governors of the Federal Reserve System. Washington, DC, USA (2001).
- Sakellaris P, Wilson D. Quantifying embodied technological change. Rev. Economic Dynamics7(1), 1–26 (2004).
- Lichtenberg FR. Pharmaceutical innovation, mortality reduction, and economic growth. In: Measuring the Gains from Medical Research: an Economic Approach. Murphy KM, Topel RH (Eds). University of Chicago Press, IL, USA, 74–109 (2003).
- Lichtenberg FR. Pharmaceutical knowledge – capital accumulation and longevity. In: Measuring Capital in the New Economy. Corrado C, Haltiwanger J, Sichel D (Eds). University of Chicago Press, IL, USA, 237–269 (2005).
- Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982–2001. Int. J. Health Care Finance Econ.5, 47–73 (2005).
- Lichtenberg FR, Duflos G. Pharmaceutical innovation and the longevity of Australians: a first look. Adv. Health Econ. Health Serv. Res.19, 95–117 (2008).
- Lichtenberg FR. The Impact of New Drugs on U.S. Longevity and Medical Expenditure, 1990–2003. Am. Econ. Rev.97(2), 438–443 (2007).
- Lichtenberg FR. The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978–2004. Econ. Innovation New Technol.18(5), 407–428 (2009).
- Romer P. Endogenous technical change. J. Polit. Econ.98, S71–S102 (1990).
- Schnittker J. Methuselah’s medicine: pharmaceutical innovation and mortality in the United States, 1960 to 2000. Soc. Sci. Med. (2009) (In Press).
Websites
- Bils M. Measuring the growth from better and better goods. NBER Working Paper no. 10606 www.nber.org/papers/w10606
- Lexchin J. Are new drugs as good as they claim to be? Australian Prescriber www.australianprescriber.com/magazine/27/1/2/3/
- Pollack A. Costly drugs known as biologics prompt exclusivity debate. New York Times. 22 July 2009 www.nytimes.com/2009/07/22/business/22biogenerics.html
- Lichtenberg FR. The effect of drug vintage on survival: micro evidence from Puerto Rico’s Medicaid program. NBER Working Paper No. 10884 www.nber.org/papers/w10884
- Lichtenberg FR. Pharmaceutical innovation and U.S. cancer survival, 1992–2003: evidence from linked SEER–MEDSTAT Data. Forum for Health Economics and Policy. 10(1), Article 1 (2007) www.bepress.com/fhep/10/1/1
- Lichtenberg FR, Waldfogel J. Does misery love company? Evidence from pharmaceutical markets before and after the Orphan Drug Act. Mich. Telecomm. Tech. L. Rev. 15, 335 (2009) www.mttlr.org/volfifteen/lichtenberg&waldfogel.pdf